Abciximab as a bridging strategy to overcome morphine–prasugrel interaction in STEMI patients

OBJECTIVE: The present study investigated whether the glycoprotein (GP)IIb/IIIa receptor blocker abciximab might be a successful bridging strategy to achieve adequate levels of platelet inhibition rapidly in cases where prasugrel is used in morphine‐pretreated ST‐elevation myocardial infarction (STE...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Br J Clin Pharmacol
Autores principales: Siller‐Matula, Jolanta M., Specht, Simon, Kubica, Jacek, Alexopoulos, Dimitrios, De Caterina, Raffaele, Hobl, Eva‐Luise, Jilma, Bernd, Christ, Günter, Lang, Irene M.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2016
Materias:
Drug Interactions
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5061801/
https://ncbi.nlm.nih.gov/pubmed/27366874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13053
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares